Technical Analysis for RARX - Ra Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 25.77 0.59% 0.15
RARX closed up 0.59 percent on Wednesday, September 18, 2019, on 78 percent of normal volume.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Down Up
See historical RARX trend table...

Date Alert Name Type % Chg
MACD Bullish Signal Line Cross Bullish 0.00%
Oversold Stochastic Weakness 0.00%
Slingshot Bearish Bearish Swing Setup 0.59%
Oversold Stochastic Weakness 0.59%
Oversold Stochastic Weakness 4.29%
Pocket Pivot Bullish Swing Setup 0.27%
Oversold Stochastic Weakness 0.27%
Oversold Stochastic Weakness 2.83%
Pocket Pivot Bullish Swing Setup 0.86%
Oversold Stochastic Weakness 0.86%

Older signals for RARX ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. Its peptide chemistry platform delivers enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. The company's lead product candidate is RA101495, an injection into the tissue under the skin for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). It also develops Factor D inhibition for age-related macular degeneration and geographic atrophy; Oral C5 inhibitor for refractory generalized myasthenia gravis, lupus nephritis, and central nervous system (CNS) diseases; C1s inhibition for autoimmune/CNS diseases. The company has multi-target collaboration and license agreement with Merck & Co., Inc. Ra Pharmaceuticals, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.
Medicine Biopharmaceutical Medical Specialties Diseases Immunology Antibodies Autoimmune Diseases Rare Diseases Autoimmunity Age Related Macular Degeneration Paroxysmal Nocturnal Hemoglobinuria Acquired Hemolytic Anemia Myasthenia Gravis Lupus Nephritis Pnh Therapeutics For The Treatment Of Diseases
Is RARX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 36.9632
52 Week Low 11.27
Average Volume 430,383
200-Day Moving Average 23.9461
50-Day Moving Average 30.014
20-Day Moving Average 26.615
10-Day Moving Average 25.523
Average True Range 1.42
ADX 32.99
+DI 9.9108
-DI 19.8482
Chandelier Exit (Long, 3 ATRs ) 25.96
Chandelier Exit (Short, 3 ATRs ) 28.51
Upper Bollinger Band 29.4516
Lower Bollinger Band 23.7784
Percent B (%b) 0.35
BandWidth 21.315799
MACD Line -1.2096
MACD Signal Line -1.269
MACD Histogram 0.0594
Fundamentals Value
Market Cap 582.62 Million
Num Shares 22.6 Million
EPS -2.84
Price-to-Earnings (P/E) Ratio -9.07
Price-to-Sales 0.00
Price-to-Book 3.16
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 27.92
Resistance 3 (R3) 27.75 26.88 27.56
Resistance 2 (R2) 26.88 26.33 26.96 27.44
Resistance 1 (R1) 26.32 25.99 26.60 26.49 27.32
Pivot Point 25.45 25.45 25.59 25.53 25.45
Support 1 (S1) 24.89 24.90 25.17 25.06 24.22
Support 2 (S2) 24.02 24.56 24.10 24.10
Support 3 (S3) 23.46 24.02 23.98
Support 4 (S4) 23.63